牛牛AI助理已提取核心訊息
William Hait, EVP, Chief EI and Med Officer at Johnson & Johnson, was involved in a transaction with the company's stock on February 15, 2024. The specific details of the transaction, including the number of shares traded, the nature of the shares, the transaction price, and the total value of the transaction, were not disclosed in the announcement. Consequently, the number of shares Hait holds after the transaction also remains undisclosed.
William Hait, EVP, Chief EI and Med Officer at Johnson & Johnson, was involved in a transaction with the company's stock on February 15, 2024. The specific details of the transaction, including the number of shares traded, the nature of the shares, the transaction price, and the total value of the transaction, were not disclosed in the announcement. Consequently, the number of shares Hait holds after the transaction also remains undisclosed.
強生公司執行副總裁、首席投資和醫療官威廉·海特於2024年2月15日參與了與該公司股票的交易。公告中未披露交易的具體細節,包括交易的股票數量、股票的性質、交易價格和交易的總價值。因此,交易後Hait持有的股票數量也仍未公開。
強生公司執行副總裁、首席投資和醫療官威廉·海特於2024年2月15日參與了與該公司股票的交易。公告中未披露交易的具體細節,包括交易的股票數量、股票的性質、交易價格和交易的總價值。因此,交易後Hait持有的股票數量也仍未公開。
有用
沒用